Company announcements, programme milestones, and updates from the people developing our work. Explore the classified public record below, with originating sources and original dates.
Latest source and classification records
The lead record is a podcast appearance on 
AI Ethics Now, a University of Warwick IATL podcast. Participation is not a partnership, endorsement or product assessment. Every record keeps its source relationship and evidence boundary visible.
Express Pharma · Contributed article ·
By Varun Sharma. The article examines how formulation knowledge can carry through evidence, quality, technology transfer and investment decisions. This is contributed commentary, with the original article retained by Express Pharma.
01Podcast appearance onAI Ethics Now | University of Warwick IATLVarun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.
02
Contributed analysis inPharmaphorumIn pharmaphorum, Varun Sharma argues that medicines access pilots should measure the full chain from recommendation to funded delivery and outcomes.
03
Contributed opinion inTechRadar ProIn TechRadar Pro, Varun Sharma sets out five tests for enterprise AI control across provenance, infrastructure, legal authority and safe exit.
04
Founder commentary inET PharmaIn ET Pharma, Varun Sharma argues that pharmaceutical quality depends on what an organisation can prove after inspection: whether failures recur, remediation holds and accountable people can trace each decision.
Classified public record
Source identification
Follow a publisher to its own website, or open a dated record below for the original headline and source. Marks identify the source; inclusion does not imply endorsement, partnership or independent validation.
AI Ethics Now | University of Warwick IATLPublisher websitePharmaphorumPublisher websiteTechRadar ProPublisher websiteET PharmaPublisher website
Financial TimesPublisher website
Pharmaceutical TechnologyPublisher website
BusinessCloudPublisher website
Manufacturing ChemistPublisher website
PharmaTimesPublisher website
Startups MagazinePublisher website
Insider MediaPublisher website
Daily BusinessPublisher website
TheBusinessDesk.comPublisher website
Yorkshire PostPublisher website
York PressPublisher website
Digital HealthPublisher websiteSekberNewsPublisher website
GeneOnlinePublisher website
Gazette & HeraldPublisher website
Yahoo News UKPublisher website
PharmaPressPublisher website
PE DealsPublisher website
Biorenewables Development CentrePublisher website
Glasgow Ecosystem | DealroomPublisher website
Drug Discovery & DevelopmentPublisher websiteThe York BriefPublisher websiteNewsroom desks
Each desk gathers related reporting and commentary into one evidence trail. That gives you the origin, the later coverage and the boundary between a proposal, a feasibility record and demonstrated delivery.
Where AI assistance ends, who owns the consequential decision and what genuine enterprise control requires.
Podcast appearance onAI Ethics Now | University of Warwick IATLPodcast appearanceAI and Accountability: When Does a Suggestion Become a Decision?Contributed opinion inTechRadar ProContributed opinionFive questions to test whether an AI stack is truly under your controlFounder commentary inBusinessCloudFounder commentaryWhy neurodivergent founders can excel at building complex systemsHow inspection, remediation evidence, human judgement and board accountability can support durable pharmaceutical quality.
What must happen between evidence, recommendation, a governed decision and reliable delivery.
Contributed analysis inPharmaphorumContributed analysisApproval is not access: Pilots' real test is implementationExpert commentary inManufacturing ChemistExpert commentaryNICE approval is not enough: why the UK's next medicines challenge is operational deliveryFounder commentary inPharmaTimesFounder commentaryHow we rollFounder letter published byFinancial TimesFounder letterLetter: The real test is whether invention leads to adoptionHow Varun Sharma’s operating experience, neurodivergence and family business origins shape NEUVIOR.
One originating implementation proposal and the international record that followed it.
Founder viewpoint inPharmaceutical TechnologyFounder viewpointWhy the India-UK trade deal now needs a five-gate implementation ledgerDerivative coverage bySekberNewsDerivative coverageIndia-UK Pharma Trade Deal: Moving Beyond Tariff ReductionsDerivative coverage byGeneOnlineDerivative coverageFive-Gate Framework Proposed for India-UK Pharmaceutical Trade Agreement ImplementationDated publisher records concerning historical research activity, while the work’s confidential scope and the boundary between activity and proof remain visible.
Publisher records concerning early feasibility support, without converting support into adoption, endorsement or technical validation.
Editorial mention byDaily BusinessEditorial roundupNEUVIOR company funding update | Daily BusinessCompany coverage byTheBusinessDesk.comRelease derived reportingNEUVIOR company support coverage | TheBusinessDesk.comEditorial mention byDigital HealthEditorial roundupDigital Health Coffee Time Briefing
Illustrative microscopy photography alongside the public news record. The people and setting are independent of NEUVIOR’s staff, premises and reported research; the source image contains no identifiable scientific finding.
microgen / Stevica Mrdja · Scientists Use Microscope for Medical Research in LaboratoryEnvato Elements commercial licence
Full frame retained; EXIF orientation honoured, proportionally resized and encoded as WebP. No crop, creative colour grading, compositing or generative changes.
Readers and journalists
A published letter, independent report, founder article and syndicated recap carry different kinds of information. Follow their relationships before deciding what a headline establishes. This view helps you find the original source, recognise who is speaking and choose a useful next question without treating visibility as product evidence.
Editorial decision model, not measured NEUVIOR results. Sources identify the published context; selected lenses do not establish product performance, customer adoption or institutional endorsement.
A journalist may need the original contribution, a precise company description or a clarification about historical reporting. This lens keeps the author, publisher and date visible. It supports a focused enquiry without treating the presence of an outlet as endorsement or permission to reproduce its material.
Specify the record and the fact you want to clarify.
A diligence reader should distinguish one funding announcement from its many recaps, and a founder opinion from an independently tested outcome. Trace each record to its source, then ask what additional material would be needed to assess the company or a particular proposed evaluation.
Identify the claim that needs a primary record.
A founder contribution presents an argument or perspective under a byline. Independent reporting involves an outlet describing the company or its work. Both can be valuable to a reader, while neither automatically establishes the performance of a medicines product.
The named author, classification and original publisher.
A useful next stepOpen the original byline and publication context.
The newsroom is most useful when the relationship between each record and its evidence remains visible.
After publication · A series by Varun Sharma
Each reflection returns to a published record and asks what the underlying issue means for the reader, for NEUVIOR and for the work that still has to be earned.
Read the complete seriesSource article
Founder commentary inBusinessCloudWhy neurodivergent founders can excel at building complex systemsFounder reflection · 3 August 2026
If your mind sees the whole system at once, the next challenge is making that insight legible, owned and repeatable for everyone who must act on it.
Read the reflectionSource article
Expert commentary inManufacturing ChemistNICE approval is not enough: why the UK's next medicines challenge is operational deliveryFounder reflection · 3 August 2026
A recommendation can clarify what should be available. You still need an accountable route from evidence to a local decision, delivery and review.
Read the reflectionFounder reflection · 3 August 2026
Before you choose the number that supports a decision, make the population, price basis, time window and source visible.
Read the reflectionSource article
Founder commentary inStartups MagazineWhat my dad's corner shop taught me | Startups MagazineFounder reflection · 3 August 2026
The smallest amount can reveal whether a business understands its margins, respects its records and keeps the promises hidden inside the numbers.
Read the reflectionSource article
Founder viewpoint inPharmaceutical TechnologyWhy the India-UK trade deal now needs a five-gate implementation ledgerFounder reflection · 3 August 2026
A trade agreement can change the commercial and policy context. The value depends on whether each implementation gate has evidence, ownership and a route to learning.
Read the reflectionFounder reflection · 3 August 2026
Feasibility becomes useful when the question, constraints, evidence threshold and stop or continue decision are explicit before the work begins.
Read the reflectionFounder reflection · 3 August 2026
Support matters when it converts expensive uncertainty into a clearer product, technical, commercial or stop decision.
Read the reflectionSource article
Founder letter published byFinancial TimesLetter: The real test is whether invention leads to adoptionFounder reflection · 3 August 2026
Invention creates a possibility. Adoption requires authority, evidence, implementation, review and a reason for people to change what they do.
Read the reflectionHow to read this newsroom
A media mention, founder article, letter, public support record or secondary pickup does not by itself establish NHS involvement, customer adoption, regulatory approval, clinical efficacy, validated healthcare outcomes, manufacturing capability or publisher endorsement.
Every record is classified so you can distinguish original reporting, release derived reporting, founder opinion, editorial roundups and derivative coverage before drawing a conclusion.
Public record index
Find the original internal record for every supplied article, letter, commentary and secondary pickup. Classification stays visible so a derivative mention never reads like a separate endorsement.
01AI Ethics Now | University of Warwick IATLVarun Sharma joins AI Ethics Now to examine false confidence, human responsibility and the point where AI assisted suggestions become accountable decisions.
02PharmaphorumIn pharmaphorum, Varun Sharma argues that medicines access pilots should measure the full chain from recommendation to funded delivery and outcomes.
03TechRadar ProIn TechRadar Pro, Varun Sharma sets out five tests for enterprise AI control across provenance, infrastructure, legal authority and safe exit.
04ET PharmaIn ET Pharma, Varun Sharma argues that pharmaceutical quality depends on what an organisation can prove after inspection: whether failures recur, remediation holds and accountable people can trace each decision.
05Financial TimesA Financial Times founder letter arguing that invention is only the beginning of the work required for adoption. The source is a published reader letter, not Financial Times staff coverage of NEUVIOR, and subscriber access may be required.
06Pharmaceutical TechnologyPharmaceutical Technology coverage of Varun Sharma’s proposed five gate implementation ledger. The proposal is a founder viewpoint, not an adopted government, regulator or industry framework.
07GeneOnlineSecondary record
An AI labelled derivative recap of Varun Sharma’s Pharmaceutical Technology commentary, retained as a derivative record rather than an independent endorsement.
08Secondary record
A derivative adaptation of the five gate implementation argument, linked to its originating Pharmaceutical Technology commentary.
09Drug Discovery & DevelopmentSecondary record
A network republication concerning publicly reported SMART:SCOTLAND support for NEUVIOR.
Open classified record
10PharmaTimesA founder commentary about why several medicines measures can each be legitimate while still requiring reconciliation, ownership and a shared operating view.
Open classified record
11Manufacturing ChemistManufacturing Chemist commentary on the operational work required after a positive NICE recommendation. Recommendation is one milestone; it is not marketing authorisation or evidence that NEUVIOR has delivered a service or outcome.
12Digital HealthDigital Health’s editorial briefing included publicly reported SMART:SCOTLAND support for NEUVIOR.
13PharmaPressA publisher record concerning publicly reported SMART:SCOTLAND support for NEUVIOR.
Open classified record
14Glasgow Ecosystem | DealroomSecondary record
An aggregated Glasgow ecosystem record concerning publicly reported SMART:SCOTLAND support for NEUVIOR.
Open classified record
15Daily BusinessA Scottish business news brief recording publicly reported SMART:SCOTLAND support for NEUVIOR.
Open classified record
16TheBusinessDesk.comScottish regional business coverage recording publicly reported SMART:SCOTLAND support for NEUVIOR.
Open classified record
17PE DealsSecondary record
A dated transaction database recap derived from TheBusinessDesk’s reporting. It is retained as derivative coverage rather than a separate independent endorsement.
18Startups MagazineVarun Sharma, Founder, CEO & CTO of NEUVIOR, reflects on how early lessons in his father's corner shop shaped his approach to building complex pharmaceutical and AI systems.
Open classified record
19Manufacturing ChemistTrade coverage of bounded NEUVIOR pharmaceutical materials research.
Open classified record
20Gazette & HeraldSecondary record
A syndicated regional record concerning historical NEUVIOR research activity. The source wording should not be read as a current drug development or clinical programme.
Open classified record
21Yahoo News UKSecondary record
A historical syndicated record concerning NEUVIOR research activity, retained as a public record entry rather than evidence of a current product, programme or operating division.
Open classified record
22Insider MediaA dated Insider Media record covering bounded NEUVIOR pharmaceutical manufacturing waste research. Publication is not evidence of adoption, capability or outcomes.
23Yorkshire PostA dated Yorkshire Post record covering bounded NEUVIOR pharmaceutical manufacturing waste research.
24York PressA dated York Press publisher record concerning NEUVIOR research activity. Despite the compressed source headline, it should not be read as evidence of a clinical or new drug trial, current manufacturing capability or outcomes.
25Biorenewables Development CentreA partner hosted record covering bounded NEUVIOR pharmaceutical materials research.
Open classified record
26A local newsletter roundup linking to bounded NEUVIOR pharmaceutical materials research coverage.
Open classified record
27BusinessCloudVarun Sharma, Founder, CEO & CTO of NEUVIOR, argues that the hard part in pharmaceuticals and AI is rarely the idea. It is turning fragmented information, regulation and execution into a system that can deliver.
Open classified recordMedia centre
Founder context
Published principles
Evidence ledger
Media enquiries